Clinical Trial 22179

Study Title

Determinants of Cancer Survivorship Among People Living with HIV (HIV/AIDS/AGING/CANCER)

Summary

The aims of this study are: 1. Estimate differences and identify determinants (clinical, behavioral, and social) of cancer survival among non-AIDS defining cancer survivors living with and without HIV. 2. Evaluate longitudinal changes in individual-level clinical (e.g., comorbidities), physical (e.g., frailty, activities of daily living), and psychosocial (e.g., depression, quality of life) outcomes after a non-AIDS defining cancer diagnosis and whether these changes differ by HIV status.

Objective

Aim 1: Estimate differences and identify determinants (clinical, behavioral, and social) of cancer survival among non-AIDS defining cancer survivors living with and without HIV. Using MWCCS data, we will examine survival differences by HIV infection for all non-AIDS defining cancers (as of 3/31/2020, n=836), and by site, anal (n=56), breast (n=79), colorectal (n=59), lung and bronchus (n=117), and prostate (n=113) cancers. Clinical, social, and behavioral measures collected at time of cancer diagnosis up to the most recent MWCCS study visit will be used. Aim 2: Evaluate longitudinal changes in individual-level clinical (e.g., general comorbidities, adherence to ART), physical (e.g., frailty, activities of daily living), and psychosocial (e.g., depression, quality of life) outcomes after a non-AIDS defining cancer diagnosis and whether these changes differ by HIV status. We will leverage longitudinal data collected from the MWCCS. We will focus on all non-AIDS defining cancers together and by site. Clinical, physical, and psychosocial measures collected over time pre- (within one year) and post-cancer diagnosis will be used. Aim 3: Explore the role of patient cancer care quality on cancer survivorship outcomes among people living with and without HIV with a non-AIDS defining cancer diagnosis. We will administer a quantitative survey to cancer patients living with HIV (n=150) and matched HIV-negative cancer patients (n=150) who have at least survived 6 months post their cancer diagnosis. We will take a sequential mixed-methods approach, and apply lessons learned from the quantitative data to carry out focus group (n= 30) interviews of cancer patients living with HIV to further contextualize results.